Alterations of TGF-β/Smad mRNA expression in atopic dermatitis following narrowband ultraviolet B...

3
LETTER TO THE EDITOR Alterations of TGF-b/Smad mRNA expres- sion in atopic dermatitis following narrow- band ultraviolet B phototherapy: Results of a pilot study Dear Sir, Defective skin barrier, immunological dysfunctions (types I and IV allergy), genetic disorders, and psy- chological factors contribute to the pathogenesis of atopic dermatitis (AD). Among the aforementioned factors, CD4 + Th cells are reported to play a parti- cularly crucial role in the pathogenesis of AD [1]. Transforming growth factor b (TGF-b) and its signal- ing molecules are inhibitory for B and T cells, IgE production, and mast cell proliferation, and they can induce apoptosis in eosinophils. Although TGF-b can exert its effect on many different cell types, CD4 + Th cells may be the main targets since anti-CD4 antibodies are protective in TGF-b1 knockout mice. Disruption of TGF-b signaling in T cells or a dimin- ished TGF-b/Smad expression may be involved in the development of several immune disorders [2]. In the present pilot study, we monitored the mRNA expression of TGF-b/Smad proteins in skin of AD patients who underwent a course of narrowband ultraviolet B (NB UVB) phototherapy. We studied 10 patients (seven men and three women; age range 26—55 years; mean age 39.6 years) diagnosed with extrinsic AD [1]. In addition to the patient group, 10 healthy, non-atopic, gen- der/age-matched individuals were used as control subjects. The study followed a protocol approved by our institutional review board. All subjects who participated in the investigation signed an informed consent. NB UVB phototherapy was performed using the Cosmedico GP-42 (Cosmedico Medizintechnik GmbH, VS-Schwenningen, Germany) cabin fitted with ARIMED 311 fluorescent lamps. Irradiation was performed thrice weekly for 6 weeks. Starting dose was 0.1 J/cm 2 NB UVB for skin type II and 0.2 J/ cm 2 for skin type III. Depending on tolerability and skin type, NB UVB dosage was increased with 0.1— 0.2 J/cm 2 . Maximum NB UVB dose was considered 1.5 and 1.8 J/cm 2 , respectively [3]. Additional ther- apy was restricted to the use of emollients. Assess- ment of disease activity at baseline and after phototherapy was performed using the Six Area, Six Sign, AD (SASSAD) score [4]. In AD patients, one 3-mm full-thickness skin spe- cimen was taken from lesional skin before the first NB UVB irradiation and one specimen was recovered from an area adjacent (about 2 cm) to the pre- treatment biopsy site 12 h following the last NB UVB exposure. Moreover, a 3-mm full-thickness skin specimen was taken from healthy controls. In order to perform quantitative analysis of real-time RT-PCR total cellular RNA was isolated from skin tissue samples using RNeasy 1 Lipid Tissue Kit (QIAGEN, Chatsworth, CA) following the manufacturer’s pro- tocol. Real-time PCR for TGF-b1, Smad3/4/7, and GAPDH was performed according to standard pro- cedures as previously described [5]. Data analysis was performed using the statistical package Med- Calc Software (Mariakerke, Belgium). Non-normal distribution of data was confirmed by the D’Agos- tino—Pearson test. Results were analysed using paired or independent non-parametric tests includ- ing the Wilcoxon-rank test, Mann—Whitney test, and Spearman rank correlation procedure, respectively. We constrained experimentwise error rates due to multiple comparisons to the standard alpha (P) level of 0.05 by the Bonferroni method. A significant (P < 0.05) reduction of the median baseline SASSAD score from 45 to 17 was observed after phototherapy. Healthy skin of control subjects showed significantly (P < 0.05) higher Smad3/4 Journal of Dermatological Science (2006) 44, 56—58 www.intl.elsevierhealth.com/journals/jods KEYWORDS Atopic eczema; Signal transduction; TGF-beta; Smad proteins; TL-01; UVB 0923-1811/$30.00 # 2006 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.jdermsci.2006.06.004

Transcript of Alterations of TGF-β/Smad mRNA expression in atopic dermatitis following narrowband ultraviolet B...

Page 1: Alterations of TGF-β/Smad mRNA expression in atopic dermatitis following narrowband ultraviolet B phototherapy: Results of a pilot study

Journal of Dermatological Science (2006) 44, 56—58

www.intl.elsevierhealth.com/journals/jods

LETTER TO THE EDITOR

Alterations of TGF-b/Smad mRNA expres-sion inatopicdermatitis followingnarrow-band ultraviolet B phototherapy: Resultsof a pilot study

KEYWORDSAtopic eczema;Signal transduction;TGF-beta;Smad proteins;TL-01;UVB

Dear Sir,

Defective skin barrier, immunological dysfunctions(types I and IV allergy), genetic disorders, and psy-chological factors contribute to the pathogenesis ofatopic dermatitis (AD). Among the aforementionedfactors, CD4+ Th cells are reported to play a parti-cularly crucial role in the pathogenesis of AD [1].Transforming growth factor b (TGF-b) and its signal-ing molecules are inhibitory for B and T cells, IgEproduction, and mast cell proliferation, and theycan induce apoptosis in eosinophils. Although TGF-bcan exert its effect on many different cell types,CD4+ Th cells may be the main targets since anti-CD4antibodies are protective in TGF-b1 knockout mice.Disruption of TGF-b signaling in T cells or a dimin-ished TGF-b/Smad expression may be involved inthe development of several immune disorders [2]. Inthe present pilot study, we monitored the mRNAexpression of TGF-b/Smad proteins in skin of ADpatients who underwent a course of narrowbandultraviolet B (NB UVB) phototherapy.

We studied 10 patients (seven men and threewomen; age range 26—55 years; mean age 39.6years) diagnosed with extrinsic AD [1]. In additionto the patient group, 10 healthy, non-atopic, gen-der/age-matched individuals were used as controlsubjects. The study followed a protocol approved by

0923-1811/$30.00 # 2006 Japanese Society for Investigative Dermadoi:10.1016/j.jdermsci.2006.06.004

our institutional review board. All subjects whoparticipated in the investigation signed an informedconsent. NB UVB phototherapy was performed usingthe Cosmedico GP-42 (Cosmedico MedizintechnikGmbH, VS-Schwenningen, Germany) cabin fittedwith ARIMED 311 fluorescent lamps. Irradiationwas performed thrice weekly for 6 weeks. Startingdose was 0.1 J/cm2 NB UVB for skin type II and 0.2 J/cm2 for skin type III. Depending on tolerability andskin type, NB UVB dosage was increased with 0.1—0.2 J/cm2. Maximum NB UVB dose was considered1.5 and 1.8 J/cm2, respectively [3]. Additional ther-apy was restricted to the use of emollients. Assess-ment of disease activity at baseline and afterphototherapy was performed using the Six Area,Six Sign, AD (SASSAD) score [4].

In AD patients, one 3-mm full-thickness skin spe-cimen was taken from lesional skin before the firstNB UVB irradiation and one specimen was recoveredfrom an area adjacent (about 2 cm) to the pre-treatment biopsy site 12 h following the last NBUVB exposure. Moreover, a 3-mm full-thickness skinspecimen was taken from healthy controls. In orderto perform quantitative analysis of real-time RT-PCRtotal cellular RNA was isolated from skin tissuesamples using RNeasy1 Lipid Tissue Kit (QIAGEN,Chatsworth, CA) following the manufacturer’s pro-tocol. Real-time PCR for TGF-b1, Smad3/4/7, andGAPDH was performed according to standard pro-cedures as previously described [5]. Data analysiswas performed using the statistical package Med-Calc Software (Mariakerke, Belgium). Non-normaldistribution of data was confirmed by the D’Agos-tino—Pearson test. Results were analysed usingpaired or independent non-parametric tests includ-ing theWilcoxon-rank test, Mann—Whitney test, andSpearman rank correlation procedure, respectively.We constrained experimentwise error rates due tomultiple comparisons to the standard alpha (P) levelof 0.05 by the Bonferroni method.

A significant (P < 0.05) reduction of the medianbaseline SASSAD score from 45 to 17 was observedafter phototherapy. Healthy skin of control subjectsshowed significantly (P < 0.05) higher Smad3/4

tology. Published by Elsevier Ireland Ltd. All rights reserved.

Page 2: Alterations of TGF-β/Smad mRNA expression in atopic dermatitis following narrowband ultraviolet B phototherapy: Results of a pilot study

Letter to the Editor 57

Fig. 1 Diagram showing expression of TGF-b1/Smadproteins in lesional skin of 10 atopic dermatitis patientsassessed before (AD pre) and after (AD post) a 6-weekcourse of NB UVB phototherapy. For comparison, expres-sion of TGF-b1/Smad proteins in skin of 10 healthy sub-jects is also shown (Controls).

mRNA expression as compared to AD patients(Fig. 1). However, mRNA expression of Smad7 andTGF-b1 observed in controls did not significantly(P > 0.05) differ from AD patients. There was asignificant increase of mRNA expression ofSmad3/4 (P < 0.05) after NB UVB phototherapy.Nevertheless, post-treatment mRNA levels ofTGF-b1 and Smad7 did not significantly (P > 0.05)differ from baseline levels (Table 1). There was nolinear relationship between the relative SASSADscore reduction and relative increase of mRNAexpression of Smad3/4 as assessed by the Spearmanrank correlation procedure (r < 0.3; P > 0.05). In aprevious study, a significantly reduced transcriptionof TGF-b has been demonstrated in skin lesionsof canine AD [6]. Moreover, TGF-b1 appears tosuppress AD-like skin lesions in mice at least inpart through down-regulation of interferon-g [7].In a human study [8], the mRNA expressionpatterns of various cytokines were examined in

Table 1 Data of quantitative real-time RT-PCR of TGF-b/Smcontrols (n = 10) and in patients with atopic dermatitisphototherapy

Parameter AD pre A

TGF-b1 (PS) F 50-GGTACCTGAACCCGTGTTGCT-30

RT-PCR 0.014 (0.004—0.03) 0

Smad3 (PS) F 50-TGAGTTCGCCTTCAATATGAAGAART-PCR 0.035 (0.009—0.075) 0

Smad4 (PS) F 50-ACTGCAGAGTAATGCTCCATCAAGRT-PCR 0.067 (0.048—0.152) 0

Smad7 (PS) F 50-TAGCCGACTCTGCGAACTAGAGTRT-PCR 0.006 (0.003—0.011) 0

GAPDH (PS) F 50-CCTCAACTACATGGTTTACA-TGT

PS, primer sequence; GAPDH, Glyseraldehyde-3-phosphate dehydro

untreated lesional skin of patients with extrinsicAD, intrinsic AD, and healthy skin of normalsubjects. However, the authors did not observedifferences of TGF-b mRNA levels among threegroups. Toda et al. [9] evaluated the expressionof TGF-b1 bymeans of immunohistochemistry. Theyobserved that TGF-b1 expression was markedlyenhanced in both acute and particularly chroniclesions of AD.

Our study support data of previous studiesdemonstrating the high efficacy of NB UVB in thetreatment of AD [3]. In accordance with the findingsof Jeong et al. [7], we did not observe significantdifferences between TGF-b1 mRNA expressionfound in AD and healthy skin. However, we observedin skin of AD patients significantly decreased levelsof receptor-regulated (Smad3) and common media-tor (Smad4) intracellular signal transducers whichusually propagate TGF-b1 signals and regulateexpression of target genes [2]. After phototherapy,we observed a significant increase of mRNA expres-sion of Smad3/4 which was paralleled with a sig-nificant improvement of the patients’ skin status.Indeed, the design of the present pilot study doesnot allow to draw the conclusion that the improve-ment of AD was due to the increase of Smad3/4mRNA expression, the less the since we did notobserve a significant correlation between thechanges of the clinical score and the increase ofSmad mRNA expression. Quan et al. [10] have shownthat UVB blocks in vitro cellular responsiveness toTGF-b through down-regulation of TGF-b type IIreceptor and induction of Smad7. They also per-formed an in vivo study on healthy subjects, whowere exposed UVB, and observed an increase ofmRNA expression for TGF-b1 (48—72 h post-irradia-tion) and Smad7 (8 h post-irradiation). Quan et al.[10] did, however, not detect significant changes in

ad mRNA [median (range)] levelsa investigated in healthy(n = 10) before (AD pre) and after (AD post) NB UVB

D post Healthy controls

, R 50-TGTTGCTGTATTTCTGGTACAGCTC-30

.015 (0.008—0.027) 0.021 (0.005—0.390)

-30, R 50-CAGGAGGTAGAACTGGTGTCTCTACTCT-30

.082 (0.057—0.082) 0.321 (0.109—1.051)

T-30, R 50-GGATGGTTTGAATTGAATGTCCTT-30

.145 (0.104—0.227) 0.454 (0.356—2.102)

-30, R 50-GGACAGTCTGCAGTTGGTTTGA-30

.007 (0.004—0.012) 0.012 (0.006—0.027)

TCC-30, R 50-ATGGGATTTCCATTGA-TGA-CAAG-30

genase.

Page 3: Alterations of TGF-β/Smad mRNA expression in atopic dermatitis following narrowband ultraviolet B phototherapy: Results of a pilot study

58 Letter to the Editor

Smad3/4 protein expression following short-termUVB exposure.

Taken together, we observed significantlyreduced mRNA expression of Smad3/4 in lesionalskin of AD patients as compared to healthy subjects.Following a 6-week course of NB UVB phototherapy,which resulted in a significant improvement of AD,the initially reduced Smad3/4 levels significantlyincreased. Our results underscore the significanceof the TGF-b/Smad signaling pathway in the etio-pathogenesis of AD. Possibly, phototherapy of ADworks through modulation of signal transducer pro-teins. Nevertheless, our results have to be substan-tiated by further studies including a larger samplesize, disease controls, such as psoriasis patients,and immunohistological studies.

References

[1] Abramovits W. Atopic dermatitis. J Am Acad Dermatol2005;53(Suppl. 1):86—93.

[2] Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Trans-forming growth factor-beta regulation of immune responses.Annu Rev Immunol 2006;24:99—146.

[3] Gambichler T, Breuckmann F, Boms S, Altmeyer P, Kreuter A.Narrowband UVB phototherapy in skin conditions beyondpsoriasis. J Am Acad Dermatol 2005;52:660—70.

[4] Berth-Jones J. Six Area, Six Sign Atopic Dermatitis (SASSAD)severity score: a simple system for monitoring diseaseactivity in atopic dermatitis. Br J Dermatol 1996;135:25—30.

[5] Giulietti A, Overbergh L, Valckx D, Decallone B, Bouillon R,Mathieu C. An Overview of real-time quantitative PCR:applications to quantify cytokine gene expression. Methods2001;25:386—401.

[6] Nuttall TJ, Knight PA, McAleese SM, Lamb JR, Hill PB.Expression of Th1, Th2 and immunosuppressive cytogenetranscripts in canine atopic dermatitis. Clin Exp Allergy2002;32:789—95.

[7] Jeong CW, Ahn KS, Rho NK, Park YD, Lee DY, Lee JH, et al.Differential in vivo cytokine mRNA expression in lesionalskin of intrinsic versus extrinsic atopic dermatitis patientsusing semiquantitative RT-PCR. Clin Exp Allergy 2003;33:1717—24.

[8] Sumiyoshi K, Nakao A, Ushio H, Mitsuishi K, Okumura K,Tsuboi R, et al. Transforming growth factor-beta1 suppressesatopic dermatitis-like skin lesions in NC/Nga mice. Clin ExpAllergy 2002;32:309—14.

[9] Toda M, Leung DY, Molet S, Boguniewicz M, Taha R, Chris-todoulopoulos P, et al. Polarized in vivo expression of IL-11and IL-17 between acute and chronic skin lesions. J AllergyClin Immunol 2003;111:875—81.

[10] Quan T, He T, Kang S, Voorhees JJ, Fisher GJ. Ultratvioletirradiation alters transforming growth factor b/Smadpathway in human skin in vivo. J Invest Dermatol 2002;119:499—506.

Thilo Gambichler*Nordwig S. TomiMarina SkryganPeter Altmeyer

Alexander KreuterDepartment of Dermatology, Ruhr-University

Bochum, Gudrunstr. 56, 44791 Bochum, Germany

*Corresponding author. Tel.: +49 234 5093458;fax: +49 234 5093409

E-mail address: [email protected](T. Gambichler)

17 March 2006